Before their introduction, clinical trials of erlotinib and gefitinib had demonstrated substantial therapeutic benefits in patients with EGFR mutation–positive lung cancer, with >50% reduction in the risk of disease progression in pooled analyses of randomized trials [5]. This evidence concerns the gene EGFR and lung cancer.